Keyphrases
Cost-effectiveness Analysis
100%
Clostridium Difficile Infection
100%
Vancomycin
100%
Fidaxomicin
100%
Quality-adjusted Life Years
60%
First Recurrence
40%
Scottish
20%
Incremental Cost-effectiveness Ratio
20%
Infection Recurrence
20%
Willingness-to-pay Threshold
20%
Clinical Outcomes
10%
Resource Use
10%
Healthcare Professionals
10%
Health Status
10%
Economic Analysis
10%
Cost-effectiveness
10%
Expert Panel
10%
Phase II Trial
10%
Markov Model
10%
Probabilistic Sensitivity Analysis
10%
Cure Rate
10%
Clinical Cure
10%
Public Healthcare
10%
One-way Sensitivity Analysis
10%
Direct Costs
10%
Pharmacology, Toxicology and Pharmaceutical Science
Clostridium Difficile Infection
100%
Vancomycin
100%
Fidaxomicin
100%
Recurrent Disease
70%
Health Status
10%
Biochemistry, Genetics and Molecular Biology
Vancomycin
100%
Peptoclostridium difficile
100%
Quality Adjusted Life Year
60%
Health Status
10%
Immunology and Microbiology
Peptoclostridium difficile
100%
Quality Adjusted Life Year
60%
Health Status
10%
Food Science
Clostridium difficile
100%